Novartis AG Peer Comparison

Metric Value Ranking
Market Cap $192.1 Billion 6/11 LLY
$715.8B		 JNJ
$349.8B		 ABBV
$299.0B		 MRK
$242.0B		 AZN
$211.5B		 NVS
$192.1B		 PFE
$147.4B		 SNY
$124.1B		 GILD
$116.0B		 BMY
$115.8B		 GSK
$75.4B
Gross Margin 74% 5/11 LLY
81%		 MRK
80%		 AZN
77%		 BMY
75%		 NVS
74%		 GSK
74%		 ABBV
71%		 PFE
70%		 JNJ
70%		 SNY
68%		 GILD
-100%
Profit Margin 25% 1/11 NVS
25%		 PFE
25%		 MRK
19%		 GILD
17%		 GSK
15%		 JNJ
12%		 ABBV
11%		 AZN
11%		 SNY
11%		 BMY
10%		 LLY
8%
EBITDA margin 44% 2/11 ABBV
49%		 NVS
44%		 BMY
38%		 GSK
33%		 JNJ
32%		 PFE
31%		 AZN
30%		 SNY
26%		 MRK
25%		 LLY
20%		 GILD
12%
Quarterly Revenue $12.8 Billion 7/11 SNY
$23.3B		 JNJ
$22.5B		 PFE
$17.7B		 MRK
$16.7B		 ABBV
$14.5B		 AZN
$13.6B		 NVS
$12.8B		 BMY
$11.9B		 LLY
$11.4B		 GSK
$10.1B		 GILD
$7.6B
Quarterly Earnings $3.2 Billion 2/11 PFE
$4.5B 		NVS
$3.2B 		MRK
$3.2B 		JNJ
$2.7B 		SNY
$2.5B 		ABBV
$1.6B 		GSK
$1.5B 		AZN
$1.4B 		GILD
$1.3B 		BMY
$1.2B 		LLY
$970.3M
Quarterly Free Cash Flow $6.0 Billion 3/11 MRK
$8.5B 		PFE
$6.1B 		NVS
$6.0B 		BMY
$5.3B 		ABBV
$5.2B 		GILD
$4.5B 		AZN
$2.0B 		GSK
$564.1M 		JNJ
-$0 		LLY
-$458.9M 		SNY
-$553.8M
Trailing 4 Quarters Revenue $48.9 Billion 7/11 JNJ
$87.7B		 SNY
$74.6B		 MRK
$63.2B		 PFE
$60.1B		 ABBV
$55.5B		 AZN
$51.2B		 NVS
$48.9B		 BMY
$47.4B		 LLY
$40.9B		 GSK
$40.3B		 GILD
$28.3B
Trailing 4 Quarters Earnings $17.6 Billion 1/11 SNY
$23.3B 		JNJ
$22.5B 		PFE
$17.7B 		MRK
$16.7B 		ABBV
$14.5B 		AZN
$13.6B 		NVS
$12.8B 		BMY
$11.9B 		LLY
$11.4B 		GSK
$10.1B 		GILD
$7.6B
Quarterly Earnings Growth 81% 3/11 LLY
1790% 		PFE
287% 		NVS
81% 		SNY
57% 		AZN
4% 		ABBV
-12% 		GSK
-28% 		MRK
-33% 		BMY
-37% 		GILD
-43% 		JNJ
-90%
Annual Earnings Growth 102% 2/11 MRK
192% 		NVS
102% 		LLY
60% 		SNY
6% 		AZN
-5% 		PFE
-8% 		GSK
-34% 		ABBV
-35% 		JNJ
-65% 		GILD
-98% 		BMY
-189%
Quarterly Revenue Growth 6% 8/11 SNY
99% 		PFE
34% 		LLY
20% 		AZN
18% 		GSK
10% 		BMY
8% 		GILD
7% 		NVS
6% 		JNJ
5% 		ABBV
4% 		MRK
4%
Annual Revenue Growth -9% 10/11 LLY
330% 		SNY
57% 		PFE
17% 		GSK
12% 		AZN
12% 		BMY
6% 		GILD
5% 		MRK
3% 		ABBV
0% 		NVS
-9% 		JNJ
-10%
Cash On Hand $13.6 Billion 2/11 MRK
$14.6B 		NVS
$13.6B 		BMY
$7.9B 		SNY
$7.5B 		ABBV
$7.3B 		AZN
$4.8B 		GSK
$3.8B 		LLY
$3.4B 		PFE
$1.1B 		GILD
-$0 		JNJ
-$0
Short Term Debt $6.8 Billion 3/11 ABBV
$12.6B 		SNY
$10.5B 		NVS
$6.8B 		GSK
$4.3B 		MRK
$3.1B 		PFE
$2.9B 		LLY
$2.1B 		AZN
$1.6B 		BMY
$1.1B 		GILD
-$0 		JNJ
-$0
Long Term Debt $23.8 Billion 7/11 ABBV
$58.5B		 PFE
$58.0B		 BMY
$48.7B		 MRK
$35.0B		 AZN
$30.0B		 LLY
$29.0B		 NVS
$23.8B		 GSK
$17.4B		 SNY
$13.7B		 GILD
$0		 JNJ
$0
PE 10.91 10/11 GILD
920.26		 LLY
85.52		 ABBV
58.31		 PFE
34.80		 AZN
32.56		 JNJ
23.82		 MRK
19.92		 GSK
14.58		 SNY
14.35		 NVS
10.91		 BMY
-1.00
PS 3.92 6/11 LLY
17.52		 ABBV
5.38		 AZN
4.13		 GILD
4.10		 JNJ
3.99		 NVS
3.92		 MRK
3.83		 PFE
2.45		 BMY
2.44		 SNY
1.51		 GSK
1.46
PB 4.42 7/11 LLY
49.98		 ABBV
49.25		 BMY
6.73		 MRK
5.43		 AZN
5.18		 JNJ
4.89		 NVS
4.42		 GSK
4.27		 GILD
2.71		 PFE
1.84		 SNY
1.55
PC 14.11 9/11 LLY
212.46		 PFE
134.98		 AZN
44.09		 ABBV
41.20		 GSK
19.86		 SNY
16.62		 MRK
16.59		 BMY
14.68		 NVS
14.11		 GILD
-1.00		 JNJ
-1.00
Liabilities to Equity 1.39 7/11 ABBV
22.77		 BMY
4.46		 LLY
4.30		 GSK
3.08		 MRK
1.64		 AZN
1.57		 NVS
1.39		 PFE
1.38		 SNY
0.78		 GILD
0.00		 JNJ
-1.00
ROA 0.17 1/11 NVS
17% 		LLY
11% 		MRK
10% 		GSK
9% 		SNY
7% 		AZN
6% 		ABBV
4% 		PFE
2% 		GILD
0% 		BMY
-8% 		JNJ
-100%
ROE 0.41 3/11 ABBV
85% 		LLY
59% 		NVS
41% 		GSK
36% 		MRK
27% 		JNJ
21% 		AZN
16% 		SNY
12% 		PFE
5% 		BMY
-42% 		GILD
-100%
Current Ratio 1.72 3/11 GILD
4.65		 SNY
2.29		 NVS
1.72		 AZN
1.64		 PFE
1.63		 MRK
1.61		 GSK
1.31		 LLY
1.23		 BMY
1.22		 ABBV
1.04		 JNJ
0.00
Quick Ratio 0.23 2/11 GILD
920.26		 LLY
85.52		 ABBV
58.31		 PFE
34.80		 AZN
32.56		 JNJ
23.82		 MRK
19.92		 GSK
14.58		 SNY
14.35		 NVS
10.91		 BMY
-1.00
Long Term Debt to Equity 0.55 8/11 ABBV}
9.70		 BMY}
2.84		 LLY}
2.04		 GSK}
0.94		 MRK}
0.79		 AZN}
0.74		 PFE}
0.63		 NVS}
0.55		 SNY}
0.17		 JNJ}
0.00		 GILD}
-1.00
Debt to Equity 0.71 7/11 ABBV
11.78		 BMY
2.90		 LLY
2.19		 GSK
1.18		 MRK
0.86		 AZN
0.78		 NVS
0.71		 PFE
0.63		 SNY
0.33		 JNJ
0.00		 GILD
-1.00
Burn Rate -25.40 11/11 AZN
29.40		 SNY
16.54		 BMY
7.85		 LLY
4.74		 ABBV
1.85		 GILD
0.00		 JNJ
0.00		 PFE
-0.77		 MRK
-15.04		 GSK
-24.84		 NVS
-25.40
Cash to Cap 0.07 1/11 NVS
0.07		 BMY
0.07		 MRK
0.06		 SNY
0.06		 GSK
0.05		 ABBV
0.02		 AZN
0.02		 PFE
0.01		 GILD
0.00		 JNJ
0.00		 LLY
0.00
CCR 1.87 5/11 BMY
4.35		 GILD
3.63		 ABBV
3.33		 MRK
2.69		 NVS
1.87		 AZN
1.42		 PFE
1.36		 GSK
0.38		 JNJ
0.00		 SNY
-0.22		 LLY
-0.47
EV to EBITDA 37.21 8/11 LLY}
330.76		 GILD}
130.58		 MRK}
64.93		 AZN}
58.08		 ABBV}
51.52		 JNJ}
49.26		 GSK}
42.17		 NVS}
37.21		 PFE}
37.14		 BMY}
34.44		 SNY}
28.23
EV to Revenue 4.27 4/11 LLY
18.20		 ABBV
6.53		 AZN
4.65		 NVS
4.27		 MRK
4.20		 GILD
4.10		 JNJ
3.99		 PFE
3.40		 BMY
3.32		 GSK
2.74		 SNY
2.06

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions